Overview: Deamidated Gliadin IgA TestIntroduction: The Deamidated Gliadin IgA Test detects IgA antibodies to deamidated gliadin to diagnose celiac disease, causing bloating or diarrhea. Aligned with 2023 AGA guidelines, it uses an immunoassay for high sensitivity, aiding in autoimmune screening. This test is critical for guiding diagnosis, dietary management, and improving outcomes in immunology for patients with suspected celiac disease. It is particularly useful for individuals with gluten-related symptoms, supporting timely initiation of a gluten-free diet.
Other Names: Gliadin IgA Assay, Deamidated Gliadin Antibody Test.
FDA Status: Laboratory-developed test (LDT), meeting immunology standards for diagnostic accuracy.
Historical Milestone: Gliadin antibody testing began in the 1990s with celiac research. Deamidated assays emerged in the 2000s, improving specificity for celiac disease over older gliadin tests.
Purpose: Diagnoses celiac disease, guides gluten-free diet, and monitors IgA antibodies in patients with bloating or diarrhea.
Test Parameters: 1. Gliadin Deamidated IgA
Pretest Condition: No fasting required. Collect serum or saliva at any time. Report symptoms like bloating, diarrhea, or fatigue, and list diet (gluten exposure) or medications.
Specimen: 2-5 mL serum (SST) or 1-2 mL saliva (sterile container). Centrifuge serum within 1 hour. Transport in a biohazard bag within 8 hours.
Sample Stability at Room Temperature: 8 hours
Sample Stability at Refrigeration: 7 days
Sample Stability at Frozen: 6 months
Medical History: Document bloating, diarrhea, or history of celiac disease or gluten sensitivity. Include current diet and medications, especially immunosuppressants.
Consent: Written consent required, detailing the tests purpose, diagnostic implications, and potential need for dietary changes or further testing.
Procedural Considerations: Uses an immunoassay to detect deamidated gliadin IgA antibodies. Results are available in 1-2 days, enabling rapid clinical decisions. Performed in laboratories, often paired with other celiac tests.
Factors Affecting Result Accuracy: IgA deficiency, hemolysis, or improper storage can affect results. A recent gluten-free diet may yield false negatives, requiring gluten challenge.
Clinical Significance: Positive IgA antibodies suggest celiac disease, prompting a gluten-free diet. Negative results in symptomatic patients may require further testing, especially in IgA-deficient individuals.
Specialist Consultation: Consult a gastroenterologist for result interpretation and dietary management planning.
Additional Supporting Tests: Tissue transglutaminase IgA, small bowel biopsy, or HLA-DQ2/DQ8 testing to confirm celiac disease diagnosis.
Test Limitations: IgA deficiency may cause false negatives, necessitating IgG-based testing. Results require clinical correlation and dietary history.
References: AGA Celiac Guidelines, 2023; Gastroenterology, Rubio-Tapia A, 2022.
